Trimeton 10 mg/1 ml soluzione iniettabile

DRUG2 trials

Sponsors

Rheacell GmbH & Co. KG, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

Primary Membranous NephropathyRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Phase 2

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Active, not recruitingCTIS2024-515857-93-00

Istituto Di Ricerche Farmacologiche Mario NegriPrimary Membranous Nephropathy

Start: 2021-12-17Target: 20Updated: 2024-12-20

Phase 3

A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)

RecruitingCTIS2022-500266-10-00

Rheacell GmbH & Co. KGRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Start: 2023-06-13Target: 119Updated: 2025-12-02